Beinaglutide (Synonyms: GLP-1 (human)) |
رقم الكتالوجGC65080
One-Click Copy Product Info
|
Beinaglutide هو GLP-1 بشري مؤتلف (rhGLP-1) يشترك في التماثل بنسبة 100 ٪ مع GLP-1 البشري (7-36)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 123475-27-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Beinaglutide is a recombinant human glucagon-like peptide-1 (GLP-1) analog, sharing nearly 100% homology with human GLP-1(7-36)[1-2]. Beinaglutide activates the GLP-1 receptor to promote insulin secretion, inhibit glucagon release, and delay gastric emptying, thereby exerting dose-dependent effects in blood glucose control, food intake suppression, and body weight reduction[3-4].
In vitro, when 3T3-L1 adipocytes or primary adipocytes were pretreated with Beinaglutide for 48 hours and then co-stimulated with insulin (10nM) for 5 minutes, phosphorylation of Akt protein in the insulin signaling pathway was significantly enhanced. Additionally, Beinaglutide substantially altered the composition of glycerophospholipids (such as PC, PE) and sphingolipids (such as Ceramide) in adipocytes, reducing the content of the pro‑inflammatory lipid Ceramide[5].
In vivo, Beinaglutide (0.6–2.4mg/kg) was administered via subcutaneous injection three times daily for 2–4 weeks to diet‑induced obese (DIO) ob/ob mice or ob/ob‑NASH mouse models. Beinaglutide significantly reduced body weight gain, improved insulin sensitivity, and alleviated hepatic steatosis[6].
References:
[1] Chen K, Chen L, Shan Z, et al. Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study. Diabetes Obes Metab. 2024 Feb;26(2):690-698.
[2] Han CY, Lu JP, Ye XM, et al. Effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies in patients with type 2 diabetes: a randomized clinical trial. Front Endocrinol (Lausanne). 2023 Dec 6;14:1267503.
[3] Gao L, Huang H, Zhang L, et al. Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. Exp Clin Endocrinol Diabetes. 2022 Jun;130(6):358-367.
[4] Fan Y, Xia M, Yan H, et al. Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial. Diabetes Obes Metab. 2024 Feb;26(2):772-776.
[5] Zhang F, Chen Z, Wu D, et al. Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. iScience. 2021 Oct 30;24(12):103382.
[6] Fang X, Du Z, Duan C, et al. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. Life Sci. 2021 Apr 1;270:118966.
| Cell experiment [1]: | |
Cell lines | 3T3-L1 adipocytes (mouse preadipocyte cell line) |
Preparation Method | 3T3-L1 cells were differentiated into adipocytes in DMEM supplemented with 10% FBS, insulin, dexamethasone, and IBMX. Differentiated adipocytes were pretreated with Beinaglutide (100nM) for 48 hours in serum-free DMEM containing DPP-4 inhibitor (50μM) to prevent peptide degradation. |
Reaction Conditions | 100nM; 48h |
Applications | Beinaglutide significantly enhanced insulin-stimulated phosphorylation of Akt (Thr308 and Ser473) in 3T3-L1 adipocytes. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice and ob/ob mice |
Preparation Method | Mice were subcutaneously administered Beinaglutide (0.15–2.4mg/kg) three times daily for 2–6 weeks. For acute studies, overnight-fasted mice received a single dose 30min before glucose loading (2g/kg, i.p.) or food intake assessment. In ob/ob-NASH models, mice were fed a high-fat/high-cholesterol diet for 9 weeks prior to 4-week Beinaglutide treatment. |
Dosage form | 0.15–2.4mg/kg; s.c.; Three times daily. |
Applications |
|
References: | |
| Cas No. | 123475-27-4 | SDF | |
| المرادفات | GLP-1 (human) | ||
| Formula | C149H225N39O46 | M.Wt | 3298.61 |
| الذوبان | DMSO : 1.79 mg/mL (0.54 mM; ultrasonic and adjust pH to 5 with HCl) | Storage | Store at -20°C, protect from light, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 303.2 μL | 1.5158 mL | 3.0316 mL |
| 5 mM | 60.6 μL | 303.2 μL | 606.3 μL |
| 10 mM | 30.3 μL | 151.6 μL | 303.2 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)